441283-39-2Relevant academic research and scientific papers
Synthesis and anti-tumor activity evaluation of salinomycin C20-O-alkyl/benzyl oxime derivatives
Duan, Wenfang,Hao, Jie,Hu, Yuhua,Li, Bo,Li, Tianlei,Li, Zhongwen,Lian, Xu,Qin, Tong,Tang, Lei,Wu, Jun,Wu, Song,Zhang, Chi,Zhang, Jihong,Zhang, Wenxuan,Zhao, Xintong
supporting information, p. 870 - 876 (2022/02/03)
Seventeen C20-O-alkyl/benzyl oxime derivatives were synthesized by a concise and effective method. Most of these derivatives showed tens to several hundred nanomolar IC50 values against HT-29 colorectal, HGC-27 gastric and MDA-MB-231 breast cancer cells, whose antiproliferative activity is 15-240 fold better than that of salinomycin. The C20-oxime etherified derivatives can coordinate potassium ions, and further adjust the cytosolic Ca2+ concentrations in HT-29 cells. The significant improvement of the potency should be attributed to the better ion binding and transport ability of the modified derivatives. In addition, the C20-O-alkyl/benzyl oxime derivatives showed much better selectivity indexes (SI) than salinomycin, indicating that they present lower neurotoxic risk.
Design, synthesis and evaluation of oxime-functionalized nitrofuranylamides as novel antitubercular agents
Fan, Yi-Lei,Wu, Jian-Bing,Ke, Xing,Huang, Zhong-Ping
supporting information, p. 3064 - 3066 (2018/08/21)
A series of oxime-functionalized nitrofuranylamides were designed, synthesized and evaluated for their in vitro anti-mycobacterial activities against MTB H37Rv and drug-resistant clinical isolates. Among them, two compounds 7a and 7b exhibited excellent activity against the three tested strains. Both of them were comparable to the first-line anti-TB agents INH and RIF against MTB H37Rv, and were far more potent than INH and RIF against MDR-TB 16833 and 16995 strains. Thus, both of them could act as leads for further optimization.
ESTRATRIENE DERIVATIVES
-
Page 61-62, (2008/06/13)
Compounds and methods for modulating mesenchymal cell function, for instance smooth muscle and fibroblast proliferation or cytokine expression, and for treating conditions associated with mesenchymal cell function, for instance airway hyperresponsiveness
